Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
Recursion could receive over $300 million in additional milestone payments from the program. ・Sanofi will fund the development of the drug, with Phase 1 clinical trials expected to begin in 2027.
Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should ...
Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...
As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results